Table 1.
Recipient characteristic, eGFR and iothalamate GFR in study participants
| All | Steroid free | Steroid | |
|---|---|---|---|
| n | 134 | 107 | 27 |
| Age (years)* | 48.5 ± 12.4 | 50.1 ± 11.8 | 43.6 ± 12.9 |
| Male (%) | 60.5 | 59.3 | 64.1 |
| White (%) | 86.2 | 89.4 | 76.9 |
| BMI (kg/m2) | 26.4 ± 5.0 | 26.0 ± 4.7 | 27.3 ± 5.9 |
| BSA (m2) | 1.87 ± 0.3 | 1.87 ± 0.2 | 1.90 ± 0.3 |
| Baseline GFR measurement | |||
| n | 134 | 107 | 27 |
| Serum creatinine (mg/dL) | 1.23 ± 0.4 | 1.22 ± 0.4 | 1.25 ± 0.4 |
| iGFR | 56.2 ± 17.0 | 55.5 ± 17.0 | 58.3 ± 17.1 |
| eGFRCG | 57.6 ± 15.4 | 56.8 ± 15.5 | 60.2 ± 15.0 |
| eGFRMC | 67.6 ± 20.5 | 67.2 ± 20.1 | 69.0 ± 21.9 |
| eGFRMDRD | 63.6 ± 19.9 | 63.1 ± 20.1 | 65.2 ± 19.5 |
| eGFR CKD-EPI | 68.8 ± 20.7 | 68.0 ± 20.5 | 71.3 ± 21.5 |
| 1 year GFR measurement | |||
| n | 97 | 81 | 16 |
| Serum creatinine (mg/dL) | 1.25 ± 0.4 | 1.24 ± 0.4 | 0.26 ± 0.4 |
| iGFR | 56.4 ± 16.9 | 56.8 ± 17.7 | 56.3 ± 12.1 |
| eGFRCG | 57.5 ± 14.1 | 56.9 ± 14.5 | 60.5 ± 11.3 |
| eGFRMC | 64.2 ± 20.6 | 63.9 ± 20.8 | 65.0 ± 16.1 |
| eGFRMDRD | 59.0 ± 17.9 | 58.7 ± 18.1 | 59.4 ± 11.5 |
| eGFR CKD-EPI | 63.9 ± 18.2 | 63.2 ± 18.6 | 65.2 ± 13.5 |
BMI, body mass index; BSA, body surface area; mean ± SD; iGFR, iothalamate GFR; GFR is in milliliters per minute per 1.73 m2.
*
P < 0.05.